BCG
VRTX icon

Breakwater Capital Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Breakwater Capital Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$989K Buy
1,992
+30
+2% +$13.3K 0.12% 174
2026
Q1 		$876K Sell
1,962
-13
-0.7% -$6.06K 0.12% 175
2025
Q4 		$895K Buy
1,975
+14
+0.7% +$6.03K 0.13% 166
2025
Q3 		$768K Buy
1,961
+122
+7% +$51K 0.11% 171
2025
Q2 		$819K Buy
1,839
+53
+3% +$24.4K 0.13% 165
2025
Q1 		$866K Buy
1,786
+27
+2% +$12.6K 0.15% 133
2024
Q4 		$708K Buy
1,759
+14
+0.8% +$6.49K 0.14% 145
2024
Q3 		$812K Buy
1,745
+21
+1% +$10.1K 0.16% 128
2024
Q2 		$808K Buy
1,724
+130
+8% +$56.4K 0.18% 121
2024
Q1 		$666K Buy
1,594
+308
+24% +$130K 0.17% 124
2023
Q4 		$566K Buy
1,286
+314
+32% +$116K 0.16% 122
2023
Q3 		$359K Buy
972
+35
+4% +$12.2K 0.12% 157
2023
Q2 		$330K Buy
+937
New +$316K 0.12% 158

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Breakwater Capital Group's VRTX Position: Q2 2026 in Review

Breakwater Capital Group increased its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, buying an estimated $13.3K and bringing the position to 1,992 shares worth $989K. The position accounts for 0.12% of the portfolio, ranked #174.

Breakwater Capital Group first reported a position in VRTX in Q2 2023 and has held it in 13 quarters since. 328 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Breakwater Capital Group held 1,992 shares of Vertex Pharmaceuticals worth $989K as of Q2 2026.
  • Breakwater Capital Group bought 30 Vertex Pharmaceuticals shares in Q2 2026, an estimated $13.3K.
  • Vertex Pharmaceuticals made up 0.12% of Breakwater Capital Group's portfolio in Q2 2026, its #174 holding.
  • Breakwater Capital Group first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 328 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Breakwater Capital Group's 13F filing for Q2 2026, filed 8 Jul 2026.